Commentary

Video

Reviewing the Latest in Breast Cancer and Myeloma: Drs Tarantino and Raje

Author(s):

Yan Leyfman, MD,Noopur S. Raje, MD

OncLive® will be LIVE with OncLive® News Network: On Location at the 2024 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference

Related Videos
Peter Schmid, MD, PhD, FRCP, discusses updated KEYNOTE-522 data showing that pembrolizumab plus chemotherapy improves EFS in early-stage TNBC.
David Rimm, MD, PhD
Shaji Kumar, MD
Vered Stearns, MD
Priya U. Kumthekar, MD
David Schiff, MD
Timothy Gershon, MD, PhD
Jordan Hansford, MD
J. Bradley Elder, MD
Rimas V. Lukas, MD
Related Content
November Recap
December 2nd 2024

Revisit Every OncLive On Air Episode From November 2024

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Breast Cancer
November 27th 2024

Adjuvant Ribociclib Wins EU Approval for HR+/HER2– Early Breast Cancer

MedNews Week
September 4th 2024

Park and Graff Explore the Evolving Role of CDK4/6 Inhibitors in Metastatic Breast Cancer

Health Canada Approves Cilta-Cel in Myeloma
November 26th 2024

Health Canada Approves Cilta-Cel for Relapsed/Lenalidomide-Refractory Myeloma

The FDA accepted a BLA for 2 belantamab mafodotin–based combinations in relapsed/refractory multiple myeloma.
November 25th 2024

FDA Accepts BLA for Belantamab Mafodotin–Based Combos in R/R Myeloma